Vivos Therapeutics Inc Stock News

Vivos Therapeutics, Inc. (NASDAQ:VVOS ) Q3 2024 Earnings Conference Call November 14, 2024 5:00 PM ET Company Participants Kirk Huntsman - Chariman & CEO Brad Amman - CFO Conference Call Participants Scott Henry - Alliance Global Partners Lucas Ward - Ascendiant Capital Markets. Operator Good day, everyone, and welcome to the Vivos Therapeutics Third Quarter 2024 Earnings Conference Call.

Vivos Therapeutics (NASDAQ:VVOS), a medical technology targeting sleep issues such as obstructive sleep apnea (OSA) and snoring, had a strong third quarter marked by higher revenue and reduced operating expenses.  Revenue increased 17% year-over-year to $3.9 million compared to $3.3 million in the same period last year.

LITTLETON, Colo., Nov. 13, 2024 (GLOBE NEWSWIRE) -- Vivos Therapeutics, Inc. (“Vivos” or the “Company”) (NASDAQ: VVOS), a leading medical device and technology company specializing in the development and commercialization of highly effective proprietary treatments for sleep-related breathing disorders (including all severities of obstructive sleep apnea (OSA) in adults), today announced it plan...

Vivos Therapeutics (NASDAQ:VVOS) announced that the American Medical Association (AMA) has granted new CPT codes for the company's Vivos CARE oral medical devices. Effective January 1, 2025, these codes will streamline insurance coverage and reimbursement for Vivos' devices, designed to treat obstructive sleep apnea (OSA) in both adults and children.

New Medical Codes will Facilitate Billing by Commercial Payers for Vivos CARE Treatment for Obstructive Sleep Apnea in Adults and Children New Medical Codes will Facilitate Billing by Commercial Payers for Vivos CARE Treatment for Obstructive Sleep Apnea in Adults and Children

Vivos Therapeutics (NASDAQ:VVOS) announced that it has entered into definitive purchase agreements with institutional investors to raise proceeds of $4.3 million through the issuance and sale of an aggregate of 1,363,812 shares at $3.15 each. The company said that no stock purchase warrants are being issued in this at-the-market offering.

Vivos Therapeutics (NASDAQ:VVOS) announced that it has received US Food and Drug Administration (FDA) approval to treat moderate to severe obstructive sleep apnea (OSA) in children aged 6 to 17 using its proprietary oral medical device. This non-invasive, orthodontic-based solution offers an alternative to traditional treatments like adenotonsillectomy, which may not always be effective long-term.

Vivos is poised to disrupt the very significant pediatric obstructive sleep apnea (OSA) market with new FDA clearance and new strategic marketing and distribution model